[EN] FUMARATE-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION<br/>[FR] HYBRIDES MOLÉCULAIRES LIBÉRANT DU FUMARATE ET DU CO, LEUR UTILISATION DANS LE CADRE DU TRAITEMENT DE MALADIES INFLAMMATOIRES OU CARDIOVASCULAIRES ET LEUR PROCÉDÉ DE PRÉPARATION
申请人:UNIV PARIS VAL DE MARNE
公开号:WO2015140337A1
公开(公告)日:2015-09-24
The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
FUMARATE-CO-RELEASING MOLECULE HYBRIDS, THEIR USE IN THE TREATMENT OF INFLAMMATORY OR CARDIOVASCULAR DISEASES AND THEIR PROCESS OF PREPARATION
申请人:UNIVERSITE PARIS EST CRETEIL VAL DE MARNE
公开号:US20170174716A1
公开(公告)日:2017-06-22
The present invention relates to hybrid fumarate-CO-releasing molecules capable of increasing heme oxygenase-1 (HO-1) activity and HO-1 protein expression and simultaneously releasing CO, their synthesis and their use in therapeutic applications, in particular their use in the treatment of inflammatory or cardiovascular diseases.
US9944669B2
申请人:——
公开号:US9944669B2
公开(公告)日:2018-04-17
Synthesis, characterization, single crystal XRD and biological screenings of organotin(IV) derivatives with 4-(2-hydroxyethyl)piperazine-1-carbodithioic acid
products. Single crystal XRD study has shown skew trapezoidal- and trigonal-bipyramidal Sn(IV) in 1 and 7, respectively. Compound 6 interacted with salmon sperm DNA (SS-DNA) with significant hypochromic effect and an intercalating mode of binding. Diorganotin(IV) derivatives (2 and 3) generally exhibited poor antibacterial/antifungal potential as compared to their trialkyltin(IV)/triaryltin(IV) counterparts